Article
Oncology
Lorenzo Livi, Giuseppe Barletta, Francesca Martella, Calogero Saieva, Isacco Desideri, Carlotta Bacci, Maria Riccarda Del Bene, Mario Airoldi, Domenico Amoroso, Luigi Coltelli, Vieri Scotti, Carlotta Becherini, Luca Visani, Viola Salvestrini, Matteo Mariotti, Fulvia Pedani, Marco Bernini, Luis Sanchez, Lorenzo Orzalesi, Jacopo Nori, Simonetta Bianchi, Iacopo Olivotto, Icro Meattini
Summary: The study aimed to evaluate whether pharmacological cardioprevention could reduce subclinical heart damage in breast cancer patients undergoing anthracycline-based chemotherapy. The results of the interim analysis suggested that cardioprotective pharmacological strategies were well tolerated and appeared to protect against cancer therapy-related left ventricular ejection fraction decline and heart remodeling.
Article
Physiology
Claudia Altomare, Alessandra Maria Lodrini, Giuseppina Milano, Vanessa Biemmi, Edoardo Lazzarini, Sara Bolis, Nicolo Pernigoni, Eleonora Torre, Martina Arici, Mara Ferrandi, Lucio Barile, Marcella Rocchetti, Giuseppe Vassalli
Summary: The study found that Doxorubicin (Dox) treatment caused T-tubule disarray and significant changes in cardiac myocytes' electrical activity, which were interfered with by subsequent Trastuzumab (Trz) administration. The two drugs had different effects on intracellular Ca2+ handling, both leading to SR instability.
FRONTIERS IN PHYSIOLOGY
(2021)
Article
Oncology
Parvin F. Peddi, Peter A. Fasching, Duan Liu, Emmanuel Quinaux, Nicholas J. Robert, Vicente Valero, John Crown, Carla Falkson, Adam Brufsky, Julie M. Cunningham, Richard M. Weinshilboum, Tadeusz Pienkowski, Wolfgang Eiermann, Miguel Martin, Valerie Bee, Xiaoyan Wang, Liewei Wang, Eric Yang, Dennis J. Slamon, Sara A. Hurvitz
Summary: This study investigated the association between genetic polymorphisms and disease-free survival and cardiac toxicity in HER2-positive breast cancer patients treated with trastuzumab and/or anthracyclines. The results showed no correlation between the studied polymorphisms and disease-free survival or cardiac toxicity.
CLINICAL CANCER RESEARCH
(2022)
Article
Cardiac & Cardiovascular Systems
Husam Abdel-Qadir, David Bobrowski, Limei Zhou, Peter C. Austin, Oscar Calvillo-Arguelles, Eitan Amir, Douglas S. Lee, Paaladinesh Thavendiranathan
Summary: The study found that women exposed to statins had a lower risk of heart failure hospital presentations after chemotherapy for early breast cancer involving anthracyclines, with non-significant trends towards lower risk following trastuzumab. These findings support the development of randomized controlled trials of statins for prevention of cardiotoxicity.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Review
Oncology
Zhu-yue Ma, Shan-shan Yao, Yan-yan Shi, Ning-ning Lu, Fang Cheng
Summary: This study aimed to assess the effects of aerobic exercise (AE) on parameters related to cardiotoxicity in breast cancer patients receiving anthracycline or trastuzumab treatment. The findings of the systematic review and meta-analysis showed that AE significantly improved cardiorespiratory fitness and peak oxygen consumption (VO2 peak), and when combined with resistance exercise, it led to a lower risk of adverse effects and better results. Overall, AE was deemed safe, feasible, and promising for improving the levels of cardiotoxicity in these patients.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Medicine, General & Internal
Carolyn M. Larsen, Mariana Garcia Arango, Harika Dasari, Maria Arciniegas Calle, Effie Adjei, Juan Rico Mesa, Christopher G. Scott, Carrie A. Thompson, James R. Cerhan, Tufia C. Haddad, Matthew P. Goetz, Joerg Herrmann, Hector R. Villarraga
Summary: This retrospective case-control study compared the long-term cumulative incidence of congestive heart failure (CHF) in patients with breast cancer or lymphoma treated with anthracycline therapy compared with healthy controls. The results showed that patients had a higher risk of CHF compared with controls, and this risk persisted over time.
Article
Medicine, Research & Experimental
Lulu Cui, Jia Huang, Yongtao Zhan, Ni Qiu, Huan Jin, Jia Li, Huiqi Huang, Hongsheng Li
Summary: The study found that certain genetic polymorphisms may play a role in individual differences in myelosuppression during anthracycline-based chemotherapy. Specific polymorphic alleles were associated with a significantly decreased risk of hematologic toxicity.
Article
Medicine, Research & Experimental
Hiroaki Shima, Goro Kutomi, Yoko Kuga, Asaka Wada, Fukino Satomi, Kiminori Sato, Daisuke Kyuno, Noriko Nishikawa, Satoko Uno, Hidekazu Kameshima, Tosei Ohmura, Tadashi Hasegawa, Ichiro Takemasa
Summary: The benefit of a taxane-first sequence and adriamycin and cyclophosphamide (AC) in patients with non-clinical complete response (non-cCR) to pertuzumab, trastuzumab, and docetaxel (PTD) was investigated. A high pathological clinical response (pCR) rate was observed for the taxane-first sequence. Some patients achieved pCR without cCR after PTD alone, indicating additional antitumor effects after AC.
EXPERIMENTAL AND THERAPEUTIC MEDICINE
(2023)
Article
Multidisciplinary Sciences
Thiago Ferreira de Souza, Thiago Quinaglia Silva, Ligia Antunes-Correa, Zsofia D. Drobni, Felipe Osorio Costa, Sergio San Juan Dertkigil, Wilson Nadruz, Facricio Brenelli, Andrei C. Sposito, Jose Roberto Matos-Souza Jr, Otavio Rizzi Coelho, Tomas G. Neilan, Michael Jerosch-Herold, Otavio Rizzi Coelho-Filho
Summary: Limited data exists on how anthracyclines affect the structure, function, and tissue characteristics of the right ventricle. This study found that breast cancer patients treated with anthracyclines experienced right ventricular atrophy, systolic dysfunction, and an increase in diffuse interstitial fibrosis, indicating a cardiotoxic response similar to that observed in the left ventricle.
SCIENTIFIC REPORTS
(2021)
Article
Cardiac & Cardiovascular Systems
Belen Diaz-Anton, Rodrigo Madurga, Blanca Zorita, Samantha Wasniewski, Andrea Moreno-Arciniegas, Beatriz Lopez-Melgar, Natalia Ramirez Merino, Roberto Martin-Asenjo, Patricia Barrio, Maximiliano German Amado Escanuela, Jorge Solis, Francisco Javier Parra Jimenez, Eva Ciruelos, Jose Maria Castellano, Leticia Fernandez-Friera
Summary: This study evaluated the echocardiographic and biomarker changes in breast cancer patients undergoing chemotherapy. The findings suggest that one month after completion of anthracycline treatment is the optimal time to detect cardiotoxicity, and baseline LVEF can predict later cardiac toxicity.
Review
Biochemistry & Molecular Biology
A. C. Seara Fernando, Tais H. Kasai-Brunswick, H. M. Nascimento Jose, Antonio C. Campos-de-Carvalho
Summary: Anthracyclines are effective chemotherapeutic drugs for cancer treatment, but they can cause cardiotoxicity. Accumulation of senescent cardiac cells is an emerging mechanism associated with anthracycline-induced cardiotoxicity.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2022)
Review
Pharmacology & Pharmacy
Junqi Huang, Rundong Wu, Linyi Chen, Ziqiang Yang, Daoguang Yan, Mingchuan Li
Summary: This review summarizes the recent findings on the mitochondrial mechanisms during anthracycline cardiotoxicity, including the production of ROS and mitochondrial damage, mitochondrial iron overload and ferroptosis, autophagy, mitophagy, and disruption of cardiac metabolism.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Justin S. Kim, Andres S. Arango, Swapnil Shah, William R. Arnold, Emad Tajkhorshid, Aditi Das
Summary: By using experimental and theoretical methods, this study unveils the interactions between anthracycline derivatives and CYP2J2, which helps to understand the potential mechanism of anthracycline cardiotoxicity and aids in the design of new anthracycline derivatives with lower toxicity.
JOURNAL OF INORGANIC BIOCHEMISTRY
(2022)
Article
Biochemistry & Molecular Biology
Apiwan Arinno, Chayodom Maneechote, Thawatchai Khuanjing, Nanthip Prathumsap, Titikorn Chunchai, Busarin Arunsak, Wichwara Nawara, Sasiwan Kerdphoo, Krekwit Shinlapawittayatorn, Siriporn C. Chattipakorn, Nipon Chattipakorn
Summary: This study aims to investigate the protective effects of melatonin and metformin against trastuzumab-induced cardiac injury. The results demonstrate that both melatonin and metformin can attenuate trastuzumab-induced cardiac injury and improve cardiac function.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
(2023)
Article
Medicine, Research & Experimental
Apiwan Arinno, Chayodom Maneechote, Titikorn Chunchai, Busarin Arunsak, Sasiwan Kerdphoo, Siriporn C. Chattipakorn, Nipon Chattipakorn
Summary: This study demonstrates the potential therapeutic effects of α7nAChR and mAChR agonists in mitigating trastuzumab-induced cardiotoxicity by improving mitochondrial dysfunction, autophagic deficiency, and excessive myocyte death, thus highlighting their significance in improving cardiac function.
Article
Clinical Neurology
Adam R. Wolfe, Dukagjin Blakaj, Nyall London, Adriana Blakaj, Brett Klamer, Jeff Pan, Paul Wakely, Luciana Prevedello, Marcelo Bonomi, Aashish Bhatt, Raju Raval, Joshua Palmer, Daniel Prevedello, Mauricio Gamez, Ricardo Carrau
JOURNAL OF NEUROLOGICAL SURGERY PART B-SKULL BASE
(2020)
Article
Ophthalmology
Keyton Clayson, Thomas Sandwisch, Yanhui Ma, Elias Pavlatos, Xueliang Pan, Jun Liu
CURRENT EYE RESEARCH
(2020)
Article
Clinical Neurology
Jessica Lewis, Kimberley Scott, Xueliang Pan, Jill Heathcock
DEVELOPMENTAL NEUROREHABILITATION
(2020)
Article
Engineering, Biomedical
Julia Mazzarella, Mike McNally, Ajit M. W. Chaudhari, Xueliang Pan, Jill C. Heathcock
CLINICAL BIOMECHANICS
(2020)
Article
Clinical Neurology
Cynthia Kerson, Roger deBeus, Howard Lightstone, L. Eugene Arnold, Justin Barterian, Xueliang Pan, Vincent J. Monastra
CLINICAL EEG AND NEUROSCIENCE
(2020)
Article
Sport Sciences
Ajit M. W. Chaudhari, Margaret R. Van Horn, Scott M. Monfort, Xueliang Pan, James A. Onate, Thomas M. Best
MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
(2020)
Article
Ophthalmology
Keyton Clayson, Elias Pavlatos, Xueliang Pan, Thomas Sandwisch, Yanhui Ma, Jun Liu
TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
(2020)
Article
Pathology
Ankur K. Patel, Xueliang Pan, Diana M. Vila, Wendy L. Frankel, Wei Chen, Kyle A. Perry, Robert E. Merritt, Desmond M. D'Souza, Evan J. Wuthrick, Terence M. Williams
Summary: The study found that the presence of PNI in EAC patients during surgery is significantly associated with worse LRFS and DFS, indicating that considering adjuvant therapy in PNI patients may be beneficial.
JOURNAL OF CLINICAL PATHOLOGY
(2021)
Article
Oncology
Alexander Yaney, Ahmet S. Ayan, Xueliang Pan, Sachin Jhawar, Erin Healy, Sasha Beyer, Kylee Lindsey, Karla Kuhn, Kayla Tedrick, Julia R. White, Jose G. Bazan
Summary: The study focused on identifying esophageal dose-volume constraints associated with grade 2 esophagitis in breast cancer patients undergoing regional nodal irradiation (RNI). It was found that the rate of grade 2 esophagitis was higher with intensity modulated radiation therapy (IMRT) compared to 3D conformal radiation therapy (3DCRT). Esophageal mean dose, V10, and V20 were identified as key dosimetric parameters associated with grade 2 esophagitis.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Immunology
Aiyan Hu, Jianmin Zhu, Chunxi Zeng, Cho-Hao Lin, Jianyu Yu, Jin-Qing Liu, Kimberly Lynch, Fatemeh Talebian, Xueliang Pan, Jingyue Yan, Yizhou Dong, Zihai Li, Xue-Feng Bai
Summary: IL-27 induces robust CCL5 production by T cells, which contributes to antitumor activity.
JOURNAL OF IMMUNOLOGY
(2022)
Article
Neurosciences
Victoria A. Diedrichs, Jennifer P. Lundine, Deena Schwen Blackett, Alexandra Zezinka Durfee, Xueliang Jeff Pan, Stacy M. Harnish
Summary: Research has shown that blocked practice enhances motor skill acquisition, while random practice improves retention and transfer. This study examined the effects of blocked versus random practice in the treatment of anomia. The results indicate that both types of practice are equally effective for skill acquisition, but random practice leads to better maintenance of treatment effects.
NEUROPSYCHOLOGICAL REHABILITATION
(2023)
Article
Psychology, Clinical
Michelle E. Roley-Roberts, Xueliang Pan, Rachel Bergman, Yubo Tan, Kyle Hendrix, Roger deBeus, Cynthia Kerson, Martijn Arns, Nadja R. Ging Jehli, Shea Connor, Constance Shrader, L. Eugene Arnold
Summary: We studied the moderation effect of psychiatric comorbidities in a double-blind clinical trial of TBR NF for ADHD. 70% of ADHD patients had comorbidities, including ODD, phobias, and anxiety. Comorbidities influenced treatment response, with better response to Control for patients with anxiety alone, and slightly better response to TBR NF for other groups. After 13 months, patients with ODD alone responded better to NF than Control.
APPLIED PSYCHOPHYSIOLOGY AND BIOFEEDBACK
(2023)
Correction
Psychology, Clinical
Michelle E. E. Roley-Roberts, Xueliang Pan, Rachel Bergman, Yubo Tan, Kyle Hendrix, Roger deBeus, Cynthia Kerson, Martijn Arns, Nadja R. Ging R. Jehli, Shea Connor, Constance Schrader, L. Eugene Arnold
APPLIED PSYCHOPHYSIOLOGY AND BIOFEEDBACK
(2023)
Article
Psychology, Developmental
L. Eugene Arnold, Martijn Arns, Justin A. Barterian, Shea Connor, Roger J. deBeus, Jill A. Hollway, Cynthia Kerson, Howard Lightstone, Joel F. Lubar, Keith McBurnett, Vincent J. Monastra, Arielle Mulligan, Kristin Buchan-Page, Xueliang (Jeff) Pan, Robert Rica Jr, Michelle E. Roley-Roberts, Constance A. Schrader, Yubo Tan, Craig Williams
Summary: The study examined the delayed effects of theta-beta ratio neurofeedback for ADHD 25 months after baseline. The results showed that, despite significant improvement in the NF treatment group, there was no significant difference in parent-rated inattention compared to the control group. Most secondary measures also showed similar patterns.
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
(2023)
Article
Psychology, Clinical
Hanneke van Dijk, Roger deBeus, Cynthia Kerson, Michelle E. Roley-Roberts, Vincent J. Monastra, L. Eugene Arnolds, Xueliang Pan, Martijn Arns
APPLIED PSYCHOPHYSIOLOGY AND BIOFEEDBACK
(2020)